Health
Chulabhorn Hospital Introduces CAR-T Cell Therapy for Lymphoma
Chulabhorn Hospital has launched a new CAR-T cell therapy treatment for patients with relapsed or refractory lymphoma.
According to a report by Matichon Online on September 23, 2026, Chulabhorn Hospital has officially introduced CAR-T cell therapy as a specialized treatment option for patients suffering from lymphoma. This advanced medical innovation is specifically targeted at individuals whose cancer has returned or who have not responded to conventional treatment methods.
CAR-T cell therapy involves modifying a patient's own immune cells to better identify and attack cancer cells. For residents and long-term expatriates in Thailand, this development represents a significant expansion in local access to high-end oncology care, potentially reducing the need for patients to seek specialized treatment abroad.
While this announcement marks a milestone for the hospital's oncology department, several details remain to be confirmed. Prospective patients should note that the hospital has not yet released comprehensive information regarding the specific eligibility criteria, the total cost of the procedure, or the availability of insurance coverage for this therapy. Furthermore, as this is a highly specialized medical intervention, individuals interested in this treatment should consult directly with medical professionals at Chulabhorn Hospital to determine if it is a suitable option for their specific health condition. SawaLife does not provide medical advice; please consult with a qualified physician for all health-related decisions.